| [1] | R. Sarig and B. Rager-Zismann (1995). Measles is here to stay. Harefua, 129: 51-54. |
| [2] | R. Sarig, V. Mezger-Lallemand, I. Gitelman, C. Davis, O. Fuchs, D. Yaffe and U. Nudel (1999). Targeted inactivation of Dp71, the major non-muscle product of the DMD gene: differential activity of the Dp71 promoter during development. Hum. Mol. Gen., 8(1): 1-10. Citations: 35. |
| [3] | R. Sarig, V. Mezger-Lallemand, S. Leibovitz, and U. Nudel (2000). Increased efficiency of homologous recombination in ES cells by cleavage at both ends of homology in the targeting vector. Transgenic Res. 9(2): 79-80 |
| [4] | M. Grinberg, R. Sarig , Y. Zaltsman, D. Frumkin, N. Grammatikakis, E. Reuveny and A. Gross (2002). tBID homooligomerizes in the mitochondrial membrane to induce apoptosis. J. Biol. Chem. 277(14):12237-12245. Citations: 91. |
| [5] | Sarig R, Zaltsman Y, Marcellus RC, Flavell R, Mak TW, Gross A (2003). BID-D59A is a potent inducer of apoptosis in primary embryonic fibroblasts. J. Biol. Chem. 278(12):10707-15. Citations: 42. |
| [6] | Dalloz C*, Sarig R*, Fort P*, Yaffe D, Bordais A, Pannicke T, Grosche J, Mornet D, Reichenbach A, Sahel J, Nudel U, Rendon A (2003). (* equal contribution) Targeted inactivation of dystrophin gene product Dp71: Phenotypic impact in mouse retina. Hum. Mol. Genet. 12(13):1543-54. Citations: 56. |
| [7] | Kamer I*, Sarig R*, Zaltsman Y, Niv H, Oberkovitz G, Regev L, Haimovich G, Lerenthal Y, Marcellus RC, Gross A. (2005). (* equal contribution). Proapoptotic BID is an ATM effector in the DNA-damage response. Cell. 26;122(4):593-603. Citations: 96. |
| [8] | Sarig R, Baruchi Z, Fuchs O, Nudel U and Yaffe D. Regeneration and trans-differentiation potential of muscle derived stem cells propagated as myospheres (2006). Stem Cells, 24(7): 1769-78. |
| [9] | Kochupurakkal BS, Sarig R*, Fuchs O, Piestun D, Rechavi G, Givol D. (2007) (* equal contribution) Nanog inhibits the switch of myogenic cells towards the osteogenic lineage. Biochem Biophys Res Commun. 25;365(4):846-50. |
| [10] | Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R and Rotter V. (2008) p53 serves as a "guardian" of mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One, 2008;3(11):e3707 |
| [11] | Aharoni R, Eilam R, Aizman E, Fuchs O, Arnon R, Yaffe D, Sarig R (2009) Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in the mouse model of multiple sclerosis. J. Neuroimmunology 215(1-2):73-83. |
| [12] | Sarig R, Fuchs O, Tencer L, Panski A, Nudel U, Yaffe D (2010) Cloned myogenic cells can transdifferentiate in vivo into neuron-like cells. PLoS One. 21;5(1):e8814. |
| [13] | Brosh R , Sarig R, Bar Natan E, Molchadsky A, Madar S, Bornstein C, Buganim Y, Shapira T, Goldfinger N, Paus R and Rotter V (2010) p53-dependent Transcriptional Regulation of EDA2R and its Involvement Chemotherapy-induced Hair Loss. FEBS Lett. 584(11):2473-7. |
| [14] | Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O and Rotter V (2010) p53 plays a pivotal role in preventing malignant transformation of induced pluripotent stem cells. J. Exp. Med. 207(10):2127-40 |
| [15] | Bornstein C, Brosh R, Molchadsky A, Madar S, Goldstein I, Goldfinger N, Sarig R and Rotter V (2011) SPATA18, a spermatogenesis-associated gene, is a transcriptional target of p53. Mol Cell Biol, 31(8):1679-89. |
| [16] | Rinon A, Molchadski A, Nathan E, Yovel G, Rotter V, Sarig R and Tzahor E (2011) p53 regulates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development, 138(9):1827-38. |